CRNX
Price
$45.11
Change
+$9.22 (+25.69%)
Updated
Sep 26, 11:12 AM (EDT)
Capitalization
3.38B
41 days until earnings call
XNCR
Price
$10.67
Change
+$0.34 (+3.29%)
Updated
Sep 26, 11:12 AM (EDT)
Capitalization
736.77M
45 days until earnings call
Interact to see
Advertisement

CRNX vs XNCR

Header iconCRNX vs XNCR Comparison
Open Charts CRNX vs XNCRBanner chart's image
Crinetics Pharmaceuticals
Price$45.11
Change+$9.22 (+25.69%)
Volume$73.74K
Capitalization3.38B
Xencor
Price$10.67
Change+$0.34 (+3.29%)
Volume$100
Capitalization736.77M
CRNX vs XNCR Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. XNCR commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and XNCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (CRNX: $35.89 vs. XNCR: $10.33)
Brand notoriety: CRNX and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 152% vs. XNCR: 47%
Market capitalization -- CRNX: $3.38B vs. XNCR: $736.77M
CRNX [@Biotechnology] is valued at $3.38B. XNCR’s [@Biotechnology] market capitalization is $736.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 6 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 5 bearish.
  • XNCR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, XNCR is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а +1.16% price change this week, while XNCR (@Biotechnology) price change was +2.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.55%. For the same industry, the average monthly price growth was +7.84%, and the average quarterly price growth was +49.76%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

XNCR is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.38B) has a higher market cap than XNCR($737M). CRNX YTD gains are higher at: -29.806 vs. XNCR (-55.048). XNCR has higher annual earnings (EBITDA): -125.38M vs. CRNX (-419.62M). CRNX has more cash in the bank: 1.2B vs. XNCR (444M). CRNX has less debt than XNCR: CRNX (49.9M) vs XNCR (67.9M). XNCR has higher revenues than CRNX: XNCR (147M) vs CRNX (1.39M).
CRNXXNCRCRNX / XNCR
Capitalization3.38B737M459%
EBITDA-419.62M-125.38M335%
Gain YTD-29.806-55.04854%
P/E RatioN/AN/A-
Revenue1.39M147M1%
Total Cash1.2B444M269%
Total Debt49.9M67.9M73%
FUNDAMENTALS RATINGS
CRNX vs XNCR: Fundamental Ratings
CRNX
XNCR
OUTLOOK RATING
1..100
1024
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
62100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5046
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XNCR's Valuation (75) in the Biotechnology industry is in the same range as CRNX (89) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (62) in the Pharmaceuticals Major industry is somewhat better than the same rating for XNCR (100) in the Biotechnology industry. This means that CRNX’s stock grew somewhat faster than XNCR’s over the last 12 months.

CRNX's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as XNCR (97) in the Biotechnology industry. This means that CRNX’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's Price Growth Rating (46) in the Biotechnology industry is in the same range as CRNX (50) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to CRNX’s over the last 12 months.

XNCR's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew significantly faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXXNCR
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 5 days ago
72%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 3 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 9 days ago
75%
Bullish Trend 5 days ago
71%
Declines
ODDS (%)
Bearish Trend 5 days ago
77%
Bearish Trend 18 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVRSX27.73N/A
N/A
VY® CBRE Real Estate S
TWMTX142.77N/A
N/A
Transamerica US Growth T
HHDVX36.79N/A
N/A
Hamlin High Dividend Equity Inv
PRJDX49.46N/A
N/A
PGIM Jennison Global Opportunities R4
FIZRX37.07N/A
N/A
Macquarie Opportunity R